This website uses cookies
Read our Privacy policy and Terms of use for more information.
May 5, 2026
Obesity overtakes oncology in pipeline value, Novo’s pill is rewriting the GLP-1 race, and Lilly keeps printing cash.
Apr 30, 2026
George Church’s Rejuvenate Bio launches a crowdfunding campaign for gene therapy, meanwhile the FDA pilots real-time clinical trial data to speed drug development.
Apr 28, 2026
The entire NSF board gets fired, Lilly's latest deal, and a gene therapy helps children hear for the first time.
Apr 23, 2026
Big Pharma is going full AI mode... and Merck just dropped $1B to prove it.
Apr 21, 2026
Psychedelics get the fast lane, peptides stir controversy, and Lilly's $7B CAR-T deal.
Apr 16, 2026
Novo bets big on AI, pharma earnings season is here, and M&A is surging. Biotech is anything but quiet right now.
Apr 14, 2026
One CAR-T therapy, three diseases gone. Plus: biotech’s next trillion-dollar molecule.
Apr 9, 2026
FDA pushes for stronger ad oversight, Gilead continues its deal spree, and a two-person AI startup sparks controversy with $1.8B projections.
Apr 7, 2026
Pharma tariffs shake the market, Anthropic drops $400M on biotech, and a Lilly vs. Novo deep dive
